Retatrutide development: Phase 3 results, 2027 FDA filing, TRIUMPH trials and what comes next

Eli Lilly and Company’s retatrutide development programme is moving from its original obesity registration studies toward regulatory submission and a much broader test of whether triple hormone receptor agonism can become a platform across cardiometabolic disease. Positive results have now been disclosed from five Phase 3 retatrutide studies, including the four-trial TRIUMPH registration programme for obesity and related complications as well as the first Phase 3 TRANSCEND study in type 2 diabetes.

The immediate regulatory pathway has become substantially clearer during 2026. After reporting positive TRIUMPH-2 and TRIUMPH-3 results in July, Eli Lilly said it had the clinical data package needed to support global submissions for retatrutide as a potential treatment for obesity, knee osteoarthritis pain and moderate-to-severe obstructive sleep apnea. The company plans to submit a Biologics License Application to the U.S. Food and Drug Administration in the first quarter of 2027 after completing the Chemistry, Manufacturing and Controls package required for the filing.

Retatrutide remains investigational and has not been approved by any regulatory agency. It is not legally available as a commercial medicine, despite unapproved products being marketed online under the retatrutide name. Eli Lilly has repeatedly warned that products offered outside its clinical trials cannot be assumed to contain authentic retatrutide or to meet pharmaceutical standards for purity, strength or safety.

The development programme is also much larger than the first regulatory filing suggests. Separate Phase 3 studies are evaluating retatrutide in type 2 diabetes, cardiovascular and kidney outcomes, chronic low back pain, long-term maintenance of weight reduction and high-risk metabolic dysfunction-associated steatotic liver disease. A head-to-head Phase 3 trial against Eli Lilly’s own tirzepatide is also approaching completion, potentially providing one of the programme’s most important tests of whether the triple agonist offers enough additional clinical value to differentiate itself from Zepbound.

That breadth makes retatrutide one of the most strategically important assets in Eli Lilly’s cardiometabolic pipeline. The first commercial opportunity depends on regulatory approval for obesity and selected complications, but the longer-term value of the programme will be determined by whether its effects extend beyond percentage weight loss into diabetes control, disease-specific symptoms, treatment maintenance and major cardiovascular, kidney and liver outcomes.

What is retatrutide and how does its GIP, GLP-1 and glucagon triple-agonist mechanism differ from existing obesity drugs?

Retatrutide, also known by the development identifier LY3437943, is an investigational once-weekly injectable biologic entity that activates receptors for glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon. Eli Lilly describes the molecule as a triple hormone receptor agonist because the three activities are incorporated into a single molecule.

The design differs from medicines that activate only GLP-1 receptors and from tirzepatide, which activates both GIP and GLP-1 receptors. GLP-1 signalling is associated with appetite regulation, glucose-dependent insulin secretion and delayed gastric emptying, while GIP contributes to metabolic and glucose regulation. Glucagon-receptor activation introduces an additional pathway linked to energy metabolism and hepatic physiology, although the clinical advantages and disadvantages of combining all three mechanisms must ultimately be established through controlled trials rather than inferred from pharmacology.

Retatrutide is sometimes described informally as a “GLP-3” medicine because it engages three hormone receptors. That terminology is scientifically inaccurate. There is no GLP-3 receptor involved in retatrutide, and Eli Lilly itself identifies triple agonist as the more accurate description.

The Phase 3 programme has also explored several target doses rather than relying on a single maximum dose. Major TRIUMPH studies have used target doses including 4 mg, 9 mg and 12 mg, with stepwise escalation beginning at 2 mg. This allows regulators and clinicians to evaluate not simply maximum efficacy but the relationship between dose, weight reduction, tolerability and treatment persistence.

How did retatrutide’s Phase 2 obesity results lead Eli Lilly into the global TRIUMPH Phase 3 programme?

Retatrutide became a major obesity-development asset after a randomized Phase 2 trial involving 338 adults with obesity or overweight without diabetes. The peer-reviewed results, published in The New England Journal of Medicine in 2023, showed progressively larger weight reductions at higher doses over 48 weeks.

At 48 weeks, mean weight reduction reached 17.1% in the combined 4 mg groups, 22.8% in the combined 8 mg groups and 24.2% in the 12 mg group, compared with 2.1% for placebo. Gastrointestinal adverse events were the most common side effects, while dose-dependent increases in heart rate peaked at 24 weeks and subsequently declined.

Those findings supported progression into a much larger Phase 3 programme rather than proving the medicine ready for commercial use. Eli Lilly began the initial TRIUMPH Phase 3 programme in 2023, enrolling more than 5,800 participants across four global registration trials.

The design deliberately extended beyond uncomplicated obesity. TRIUMPH-1 combined a master obesity trial with nested studies examining knee osteoarthritis pain and moderate-to-severe obstructive sleep apnea. TRIUMPH-2 enrolled people with obesity or overweight and type 2 diabetes, TRIUMPH-3 focused on severe obesity and established cardiovascular disease, and TRIUMPH-4 concentrated on obesity or overweight accompanied by knee osteoarthritis.

The result is a registration strategy increasingly focused on obesity-related disease rather than weight reduction alone. That matters because competition in the obesity market is moving toward evidence showing whether treatment can improve specific complications and long-term health outcomes.

What did TRIUMPH-1 show about retatrutide weight loss after 80 weeks and 104 weeks of treatment?

TRIUMPH-1 is the largest and most important general-obesity study in the initial registration programme. The Phase 3 master trial randomized 2,339 participants with obesity or overweight and at least one weight-related condition, without diabetes, to retatrutide 4 mg, 9 mg or 12 mg or placebo.

Using the efficacy estimand reported by Eli Lilly, participants receiving 4 mg lost an average 19.0% of body weight at 80 weeks, those receiving 9 mg lost 25.9% and the 12 mg group lost 28.3%. The placebo group lost an average 2.2%. At the 12 mg dose, 45.3% of participants achieved at least 30% weight reduction under the same analysis.

The study also included a pre-specified 104-week extension involving 532 participants who had a baseline body mass index of at least 35, completed the main treatment period and met the extension criteria. Participants originally assigned to the 12 mg pathway and treated to their maximum tolerated dose achieved average weight reduction of 30.3% at 104 weeks under the efficacy estimand.

That 104-week result requires qualification because it came from a selected extension population rather than the entire randomized TRIUMPH-1 cohort. Participants had already completed 80 weeks of study treatment and tolerated their assigned medication, meaning the result should not be treated as the expected outcome for every patient who might eventually receive retatrutide.

The trial nevertheless provides evidence that weight reduction had not necessarily reached its maximum by 80 weeks in some participants. That creates an important development question around how long patients may continue losing weight, how maintenance dosing should be structured and whether the highest initial target dose is appropriate for every patient.

How did TRIUMPH-1 perform in knee osteoarthritis pain and moderate-to-severe obstructive sleep apnea?

TRIUMPH-1 also included nested basket trials examining two important obesity-related complications. One evaluated participants with knee osteoarthritis pain and the other included people with moderate-to-severe obstructive sleep apnea.

In the knee osteoarthritis basket, retatrutide reduced WOMAC pain subscale scores by as much as 4.3 points from an average baseline of 6.0 at 80 weeks. The WOMAC scale assesses symptoms including pain and physical function in people with osteoarthritis.

In the obstructive sleep apnea basket, the apnea-hypopnea index declined by as much as 36.1 events per hour from an average baseline of 58.6 events per hour. The apnea-hypopnea index measures the frequency of breathing interruptions during sleep and is one of the central metrics used to assess obstructive sleep apnea severity.

These results are commercially important because Eli Lilly intends to include knee osteoarthritis pain and obstructive sleep apnea in the first regulatory strategy rather than pursuing obesity alone. They also reinforce the company’s broader objective of positioning obesity medicines around treatment of associated diseases.

The findings still require regulatory evaluation. Retatrutide is not approved for knee osteoarthritis pain, obstructive sleep apnea or obesity, and company-reported changes in disease-specific endpoints should not be treated as approved claims before regulators review the complete evidence.

What did TRIUMPH-2 show for retatrutide in obesity and type 2 diabetes at 80 weeks?

TRIUMPH-2 enrolled 1,152 adults with obesity or overweight and type 2 diabetes. The study tested target doses of 4 mg, 9 mg and 12 mg against placebo over 80 weeks.

Using the efficacy estimand, participants receiving 4 mg lost an average 12.7% of body weight, those receiving 9 mg lost 19.1% and participants receiving 12 mg lost 20.8%. The placebo group lost an average 4.0%.

The study also produced improvements in glycemic control. Average A1C declined by 1.4 percentage points at 4 mg, 1.6 points at 9 mg and 1.5 points at 12 mg from a baseline of 7.7%, compared with a 0.2-point reduction for placebo.

The lower weight-loss percentages relative to TRIUMPH-1 should be interpreted in the context of the trial population rather than as a simple cross-trial efficacy ranking. Achieving large weight reductions has historically been more difficult in populations with type 2 diabetes, and the studies enrolled clinically different groups.

TRIUMPH-2 therefore adds both obesity and diabetes evidence to the registration package while overlapping with the separate TRANSCEND diabetes programme. Detailed TRIUMPH-2 results had not yet been published in a peer-reviewed journal when Eli Lilly released the July 2026 topline findings.

What did TRIUMPH-3 show in people with severe obesity and established cardiovascular disease?

TRIUMPH-3 enrolled 1,949 adults with Class 2 or Class 3 obesity and established cardiovascular disease, with or without type 2 diabetes. Participants received either retatrutide 9 mg, retatrutide 12 mg or placebo.

At 80 weeks, the 9 mg group lost an average 21.6% of body weight and the 12 mg group lost 22.6% under the efficacy estimand, compared with 3.2% for placebo.

The study also recorded cardiovascular events, but those data should be interpreted cautiously. Major adverse cardiovascular events occurred less frequently than Eli Lilly had anticipated, resulting in relatively small event numbers and wide confidence intervals.

For the pre-specified MACE-5 analysis, the pooled retatrutide groups produced a hazard ratio of 0.82 with a 95% confidence interval of 0.55 to 1.22. For MACE-3, the hazard ratio was 1.12 with a 95% confidence interval of 0.64 to 1.96. Both confidence intervals crossed 1, meaning the findings do not establish either cardiovascular benefit or cardiovascular harm.

TRIUMPH-3 should therefore not be presented as proof that retatrutide reduces cardiovascular events. Eli Lilly has a separate Phase 3 cardiovascular and kidney outcomes programme designed to answer that question over a larger and longer-duration study.

What did TRIUMPH-4 show about retatrutide weight loss and knee osteoarthritis pain?

TRIUMPH-4 produced the first successful Phase 3 readout from the retatrutide programme in December 2025. The global trial randomized 445 participants with obesity or overweight and knee osteoarthritis, without diabetes, to retatrutide 9 mg, retatrutide 12 mg or placebo.

At 68 weeks, the 9 mg group lost an average 26.4% of body weight and the 12 mg group lost 28.7% under the efficacy estimand, compared with 2.1% for placebo.

The co-primary knee-pain endpoint also improved. The 9 mg group recorded an average 4.5-point reduction on the WOMAC pain scale from a baseline of 6.0, while the 12 mg group recorded a 4.4-point reduction. Placebo produced a 2.4-point reduction.

TRIUMPH-4 is strategically important because knee osteoarthritis could become one of the first disease-specific indications attached to retatrutide if regulators accept the evidence. Obesity can increase mechanical stress on weight-bearing joints, while metabolic and inflammatory mechanisms may also contribute to disease burden.

The study cannot by itself establish how much of the pain benefit resulted directly from retatrutide pharmacology versus the effect of substantial weight reduction. From a regulatory and commercial perspective, however, the clinically measured improvement in pain is more important than determining a single mechanism behind that change.

What do the Phase 3 safety results show about nausea, gastrointestinal events, dysesthesia and treatment discontinuation?

The developing safety profile shows a consistent pattern of gastrointestinal adverse events alongside a dose-related tolerability challenge at higher retatrutide doses. Nausea, diarrhea, constipation and vomiting have been among the most frequently reported adverse events across major trials.

In TRIUMPH-1, nausea occurred in 28.6% of participants receiving 4 mg, 38.4% receiving 9 mg and 42.4% receiving 12 mg, compared with 14.8% receiving placebo. Discontinuation because of adverse events rose from 4.1% at 4 mg to 6.9% at 9 mg and 11.3% at 12 mg, compared with 4.9% for placebo.

Dysesthesia, referring broadly to abnormal or unpleasant sensations, has also emerged as an event requiring continued scrutiny. In TRIUMPH-1, it was reported in 5.1% of the 4 mg group, 12.3% of the 9 mg group and 12.5% of the 12 mg group, compared with 0.9% on placebo. Eli Lilly said the majority of these events were mild to moderate and resolved during treatment.

TRIUMPH-4 produced higher adverse-event discontinuation rates at the larger doses. Discontinuations due to adverse events occurred in 12.2% of participants receiving 9 mg and 18.2% receiving 12 mg, compared with 4.0% receiving placebo. Lilly said the rates were strongly associated with baseline body mass index and included some participants who stopped because they perceived their weight loss as excessive.

These results reinforce the importance of dose selection. The programme is no longer simply trying to establish the highest achievable percentage of weight reduction. Regulators and clinicians will also need to determine whether different doses provide useful trade-offs between efficacy, tolerability and long-term adherence.

When will Eli Lilly file retatrutide with the FDA and why is the U.S. application planned for the first quarter of 2027?

Eli Lilly currently plans to submit a Biologics License Application for retatrutide to the U.S. Food and Drug Administration in the first quarter of 2027. The company confirmed that timetable after reporting TRIUMPH-2 and TRIUMPH-3 results in July 2026 and reiterated it with its second-quarter financial results in August.

The company says the clinical data package needed to support global submissions for obesity, knee osteoarthritis pain and obstructive sleep apnea is complete. The remaining work before the U.S. application centres on completion of the comprehensive Chemistry, Manufacturing and Controls package.

CMC documentation is a fundamental part of pharmaceutical regulation rather than an administrative formality. The FDA must be satisfied that a medicine can be manufactured consistently, that its identity and quality can be controlled and that the commercial manufacturing process is adequately characterised.

Eli Lilly has committed substantial additional capital to expanding manufacturing across its global portfolio, including another $4.5 billion for Indiana manufacturing sites announced with its second-quarter 2026 results. That investment should not be characterised as spending specifically on retatrutide because the company has not allocated the entire amount to this molecule.

The planned Q1 2027 filing is therefore the next clear milestone separating the successful Phase 3 registration programme from formal regulatory review.

What is the TRANSCEND Phase 3 programme testing for retatrutide in type 2 diabetes?

Retatrutide has a separate three-trial Phase 3 programme in type 2 diabetes called TRANSCEND-T2D. The programme began in 2024 and enrolled more than 2,050 participants across different stages of diabetes treatment.

TRANSCEND-T2D-1 randomized 537 adults whose type 2 diabetes was inadequately controlled through diet and exercise alone. At 40 weeks, average A1C reductions ranged from 1.7 to 2.0 percentage points across retatrutide doses from a baseline of 7.9%. Participants receiving 12 mg lost an average 16.8% of body weight under the efficacy estimand, and weight loss had not plateaued at the end of the treatment period.

Unlike several other recent retatrutide readouts, the detailed TRANSCEND-T2D-1 findings have moved beyond a company topline announcement. Results were presented at the American Diabetes Association Scientific Sessions in June 2026 and simultaneously published in The Lancet.

TRANSCEND-T2D-2 provides an important competitive test by comparing retatrutide directly with semaglutide in adults with type 2 diabetes inadequately controlled with metformin, with or without an SGLT2 inhibitor. The approximately 1,250-participant Phase 3 trial is active but no longer recruiting, with completion activity extending into 2027.

TRANSCEND-T2D-3 is evaluating retatrutide in people with type 2 diabetes and moderate or severe renal impairment whose disease remains inadequately controlled with basal insulin, with or without metformin and an SGLT2 inhibitor. These populations give Eli Lilly a substantially broader diabetes evidence base than could be obtained from TRIUMPH-2 alone.

Why could the TRIUMPH-5 retatrutide versus tirzepatide trial become one of the programme’s most important readouts?

TRIUMPH-5 directly tests retatrutide against tirzepatide in adults with obesity. The randomized, double-blind Phase 3 study enrolled approximately 800 participants and is expected to produce its primary completion during late 2026.

This comparison is strategically important because tirzepatide is not simply an external competitor. It is Eli Lilly’s own established dual GIP and GLP-1 receptor agonist and is marketed as Zepbound for obesity.

A head-to-head comparison can therefore help answer the most commercially relevant question surrounding retatrutide: whether adding glucagon-receptor activity creates enough incremental efficacy or another meaningful clinical advantage to justify a separate place in treatment.

The answer cannot be assumed from comparisons between separate trials. Patient populations, treatment durations, study designs and statistical approaches differ across programmes, making direct randomized evidence substantially more useful than comparing headline weight-loss percentages from unrelated studies.

TRIUMPH-5 could consequently influence how Eli Lilly eventually positions retatrutide inside its own obesity franchise, even if the first FDA application is filed before all longer-term programme studies are finished.

How is TRIUMPH-6 testing whether patients can maintain weight loss on retatrutide over the long term?

TRIUMPH-6 addresses a different question from the registration trials: what happens after substantial weight loss has already been achieved.

The Phase 3b study includes an 80-week lead-in period in which participants receive retatrutide, followed by a 36-week randomized maintenance phase. Participants then continue on one of two retatrutide maintenance approaches or switch to placebo.

Approximately 643 participants are expected to take part, with primary completion currently targeted for 2028.

Maintenance evidence is commercially important because obesity is a chronic disease and weight regain after discontinuation has emerged as a major issue across the incretin drug class. A treatment strategy that can preserve substantial initial weight loss at a lower or differently structured maintenance dose could influence adherence, tolerability, drug utilisation and long-term treatment economics.

TRIUMPH-6 therefore addresses a question that maximum weight-loss trials cannot answer: how much therapy is required once a patient has already achieved a major reduction in body weight.

Which cardiovascular, kidney, chronic-pain and liver studies could expand retatrutide beyond its first FDA filing?

TRIUMPH-Outcomes is the major long-duration cardiovascular and kidney study in the programme. It is evaluating retatrutide against placebo in adults living with obesity who have established cardiovascular disease, chronic kidney disease or related elevated risk.

The importance of that study increased after TRIUMPH-3 because the cardiovascular event comparisons in TRIUMPH-3 were inconclusive. TRIUMPH-Outcomes is intended to provide the dedicated outcomes evidence required to determine whether retatrutide can reduce major cardiovascular and kidney events rather than simply improve intermediate risk factors.

TRIUMPH-7 is testing retatrutide in people with obesity or overweight and chronic low back pain. The Phase 3 study is recruiting or progressing through enrolment activity and has been designed around both change in body weight and pain intensity.

Liver disease creates another major development opportunity. SYNERGY-Outcomes is a Phase 3 master protocol evaluating retatrutide and tirzepatide in people with high-risk metabolic dysfunction-associated steatotic liver disease. The study plans to enroll about 4,500 adults and is designed to determine whether treatment can prevent major adverse liver outcomes, including progression to cirrhosis, complications of portal hypertension, liver transplantation or death.

That is a substantially higher evidentiary bar than demonstrating reduced liver fat or improvements in laboratory biomarkers. If successful, the study could establish retatrutide as a treatment affecting the progression of clinically important liver disease.

How does retatrutide fit beside Zepbound and Foundayo in Eli Lilly’s expanding obesity portfolio?

Retatrutide is entering a portfolio that has become more crowded even within Eli Lilly itself. Tirzepatide is already marketed as Zepbound for chronic weight management, while Foundayo, the brand name for oral GLP-1 drug orforglipron, received U.S. approval for obesity in April 2026.

The three medicines offer different pharmacological and delivery profiles. Zepbound is a once-weekly injectable dual GIP and GLP-1 receptor agonist. Foundayo is a once-daily oral GLP-1 receptor agonist that can be taken without food or water timing restrictions. Retatrutide is being developed as a once-weekly injectable triple GIP, GLP-1 and glucagon receptor agonist.

This creates a portfolio strategy rather than a single-product strategy. Some patients may place greater value on oral administration, others may require larger weight reductions, and specific obesity-related complications could influence which therapy is preferred.

The arrangement also creates internal competition. Retatrutide will need to demonstrate that its efficacy, disease-specific benefits or treatment flexibility justify another injectable option alongside a highly successful tirzepatide franchise.

That is why TRIUMPH-5 is particularly important. Direct evidence against tirzepatide should eventually provide a much stronger basis for positioning retatrutide than cross-trial comparisons of headline weight-loss figures.

What are the biggest regulatory, safety, manufacturing and commercial risks facing retatrutide before launch?

Regulatory approval remains the first major uncertainty. Positive Phase 3 trials do not guarantee approval, and the FDA will evaluate the complete efficacy, safety and manufacturing package before deciding whether retatrutide can be marketed and for which indications.

Dose-related tolerability is another material issue. Higher doses have generally produced larger average weight reductions but have also been associated with more gastrointestinal adverse events, dysesthesia and higher discontinuation rates in some studies.

Manufacturing creates a separate execution challenge. The global market for incretin-based obesity and diabetes treatments is already enormous, and Eli Lilly has been committing billions of dollars to new production capacity. If retatrutide is approved across several indications, the company will have to add another potentially high-volume injectable medicine to that manufacturing network while continuing to supply existing products.

Competition will also intensify before any retatrutide launch. Novo Nordisk and numerous biotechnology and pharmaceutical companies are developing next-generation injectable, oral and combination obesity treatments, while Eli Lilly itself is advancing multiple molecules.

The ultimate commercial question will therefore extend far beyond whether retatrutide can produce a high percentage of weight reduction in controlled studies. Its value will depend on the combination of efficacy, tolerability, disease-specific outcomes, treatment persistence, manufacturing capacity, reimbursement and differentiation from medicines already available when it reaches the market.

What milestones will determine whether retatrutide progresses from Phase 3 success to FDA approval and a broader cardiometabolic platform?

The most immediate milestone is completion of Eli Lilly’s CMC package followed by the planned U.S. BLA submission in the first quarter of 2027. Acceptance of that application would move retatrutide formally from late-stage clinical development into FDA review for its first proposed indications.

Publication and presentation of detailed TRIUMPH-2 and TRIUMPH-3 results will provide another important step. The July 2026 disclosures remain company-reported topline data, and clinicians will ultimately require fuller information about efficacy, discontinuations, adverse events and subgroup performance.

The TRANSCEND programme will determine how quickly type 2 diabetes becomes an additional regulatory opportunity, while TRIUMPH-5 should provide the most informative direct comparison yet between retatrutide and tirzepatide. TRIUMPH-6 will test long-term maintenance, and TRIUMPH-Outcomes and SYNERGY-Outcomes will address cardiovascular, kidney and liver questions that could take the programme far beyond conventional chronic weight management.

Retatrutide has therefore moved beyond the question that defined its early development: how much weight can a triple agonist produce? Its next phase will determine whether that magnitude of weight reduction can be converted into an acceptable long-term treatment profile and measurable benefits across diseases linked to obesity and metabolic dysfunction.

If the regulatory, safety, manufacturing and outcome pieces align, retatrutide could become a broad cardiometabolic platform rather than merely another entrant in the obesity market. The first-quarter 2027 FDA filing is the next decisive milestone, but several of the studies that may ultimately determine the programme’s strategic value will continue well beyond the first potential approval.